Share Name Share Symbol Market Type Share ISIN Share Description
Vectura Group Plc LSE:VEC London Ordinary Share GB00BKM2MW97 ORD 0.0271P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 82.50 82.10 82.30 83.30 82.00 83.30 246,025 16:35:01
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 160.5 -104.8 -13.2 - 550

Vectura Group plc Result of AGM

29/05/2019 1:25pm

UK Regulatory (RNS & others)


Vectura (LSE:VEC)
Historical Stock Chart

6 Months : From Apr 2019 to Oct 2019

Click Here for more Vectura Charts.

TIDMVEC

RNS Number : 4982A

Vectura Group plc

29 May 2019

Results of the Vectura Annual General Meeting

All Shareholder Resolutions Passed

Chippenham, UK, 29 May 2019: Vectura Group plc (LSE: VEC; "Vectura" or "the Company"), announces that all resolutions proposed to shareholders at its Annual General Meeting (AGM) held today were duly passed on a poll, the results of which are set out below:

 
  RESOLUTION                    VOTES         %        VOTES        %       VOTES         VOTES 
                                 FOR                    AGAINST              TOTAL         WITHHELD 
 To receive the Company's 
  Report and Accounts 
  for the financial 
  year ended 31 December 
  2018, including the 
  independent auditor's 
  report.                       517,998,445   100.00   4,508        0.00    518,002,953   469,421 
                               ------------  -------  -----------  ------  ------------  ----------- 
 To approve the Directors' 
  Remuneration Report 
  for the year ended 
  31 December 2018 
  (excluding the Directors' 
  Remuneration Policy).         483,282,866   94.56    27,808,998   5.44    511,091,864   7,381,219 
                               ------------  -------  -----------  ------  ------------  ----------- 
 To appoint Paul Fry 
  as a Director of 
  the Company.                  514,046,824   99.93    347,553      0.07    514,394,377   4,078,717 
                               ------------  -------  -----------  ------  ------------  ----------- 
 To appoint Anne Whitaker 
  as a Director of 
  the Company.                  514,339,705   99.99    62,129       0.01    514,401,834   4,069,450 
                               ------------  -------  -----------  ------  ------------  ----------- 
 To appoint Dr Kevin 
  Matthews as a Director 
  of the Company.               514,350,219   99.99    53,220       0.01    514,403,439   4,069,645 
                               ------------  -------  -----------  ------  ------------  ----------- 
 To re-appoint Dr 
  Per-Olof Andersson 
  as a Director of 
  the Company.                  513,861,175   99.89    546,425      0.11    514,407,600   4,065,384 
                               ------------  -------  -----------  ------  ------------  ----------- 
 To re-appoint Bruno 
  Angelici as a Director 
  of the Company.               513,162,028   99.00    5,157,967    1.00    518,319,995   153,089 
                               ------------  -------  -----------  ------  ------------  ----------- 
 To re-appoint Dr 
  Susan Foden as a 
  Director of the Company.      425,085,739   82.01    93,217,752   17.99   518,303,491   169,592 
                               ------------  -------  -----------  ------  ------------  ----------- 
 To re-appoint James 
  Ward-Lilley as a 
  Director of the Company.      518,065,321   99.95    260,624      0.05    518,325,945   147,139 
                               ------------  -------  -----------  ------  ------------  ----------- 
 To re-appoint Neil 
  Warner as a Director 
  of the Company.               514,314,164   99.98    93,697       0.02    514,407,861   4,065,223 
                               ------------  -------  -----------  ------  ------------  ----------- 
 To re-appoint Dr 
  Thomas Werner as 
  a Director of the 
  Company.                      458,303,304   88.79    57,883,040   11.21   516,186,344   2,286,739 
                               ------------  -------  -----------  ------  ------------  ----------- 
 To re-appoint Juliet 
  Thompson as a Director 
  of the Company.               472,531,745   95.86    20,428,966   4.14    492,960,711   25,512,373 
                               ------------  -------  -----------  ------  ------------  ----------- 
 To re-appoint KPMG 
  LLP as the Company's 
  auditor.                      518,284,988   99.98    106,552      0.02    518,391,540   81,544 
                               ------------  -------  -----------  ------  ------------  ----------- 
 To authorise the 
  Audit Committee to 
  determine the auditor's 
  remuneration.                 518,404,496   99.99    59,423       0.01    518,463,919   9,165 
                               ------------  -------  -----------  ------  ------------  ----------- 
 To authorise political 
  donations and expenditure.    511,974,263   98.76    6,435,501    1.24    518,409,764   61,534 
                               ------------  -------  -----------  ------  ------------  ----------- 
 To authorise the 
  Directors to allot 
  shares in the Company 
  pursuant to section 
  551 of the Companies 
  Act 2006.                     506,231,970   97.64    12,224,364   2.36    518,456,334   16,750 
                               ------------  -------  -----------  ------  ------------  ----------- 
 To authorise the 
  disapplication of 
  pre-emption rights.           514,360,381   99.96    181,300      0.04    514,541,681   3,931,403 
                               ------------  -------  -----------  ------  ------------  ----------- 
 To authorise the 
  disapplication of 
  pre-emption rights 
  in relation to an 
  acquisition or other 
  capital investment.           497,868,456   96.76    16,674,124   3.24    514,542,580   3,930,503 
                               ------------  -------  -----------  ------  ------------  ----------- 
 To authorise market 
  purchases of the 
  Company's own shares.         507,007,955   97.81    11,347,841   2.19    518,355,796   117,287 
                               ------------  -------  -----------  ------  ------------  ----------- 
 To authorise the 
  calling of any general 
  meetings of the Company 
  other than and not 
  less than 14 clear 
  days.                         511,686,911   98.69    6,783,009    1.31    518,469,920   3,164 
                               ------------  -------  -----------  ------  ------------  ----------- 
 

- Ends -

For more information, please contact:

 
Vectura Group plc 
 
David Ginivan - VP Corporate Communications                        +44 (0)7471 352 720 
 Elizabeth Knowles - VP Investor Relations                          +44 (0)7767 160 565 
 Consilium Strategic Communications                                +44 (0)20 3709 5700 
Mary-Jane Elliott / Jessica Hodgson / Susan Stuart / David Daley 
 

About Vectura

Vectura is an industry-leading inhaled product formulation, device design and development business offering a uniquely integrated inhaled drug delivery platform. We develop inhalation products to help patients suffering from airways diseases.

Vectura has ten key inhaled and eleven non-inhaled products marketed by partners with global royalty streams, and a diverse partnered portfolio of drugs in clinical development. Our partners include Hikma, Novartis, Sandoz, Mundipharma, Kyorin, Baxter, GSK, UCB, Bayer, Chiesi, Almirall, Dynavax and Tianjin KingYork.

Vectura's strategy is to fully leverage its differentiated technology and skills, maximising value by enhancing the delivery and performance of inhaled products, and through the development of high-quality generic alternatives to branded therapies.

For further information, please visit Vectura's website at www.vectura.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

RAGALMTTMBBTBPL

(END) Dow Jones Newswires

May 29, 2019 08:25 ET (12:25 GMT)

1 Year Vectura Chart

1 Year Vectura Chart

1 Month Vectura Chart

1 Month Vectura Chart
Your Recent History
LSE
VEC
Vectura
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20191022 17:09:31